In spite of advances in the treatment of pediatric acute lymphoblastic leukemia (ALL), a significant number of children with ALL are not cured of their disease. We and others have shown that signaling from the bone marrow microenvironment confers therapeutic resistance, and that the interaction between CXCR4 and stromal cell-derived factor-1 (SDF-1 or CXCL12) is a key mediator of this effect. W...

Local healing processes, including reparative angiogenesis mounted by resident vascular cells, are remarkably deteriorated in patients with diabetes. Vascular problems are worsened by the scarcity and dysfunction of circulating proangiogenic cells. Stem cell depauperization in bone marrow (BM), disruption of BM microvasculature, and alteration in chemokine signaling mechanisms concur in reducin...

BACKGROUND High-dose chemotherapy with autologous stem-cell transplantation (asct) is an accepted part of standard therapy for patients with hematologic malignancies. Usually, stem-cell mobilization uses granulocyte colony-stimulating factor (g-csf); however, some patients are not able to be mobilized with chemotherapy and g-csf, and such patients could be at higher risk of failing mobilization...

high-dose chemotherapy and autologous stem cell transplantation (sct) have become an effective care for many patients with hematological malignancies. harvesting the stem cells is one the most important parts of sct. the two most commonly used mobilization regimens are the use of granulocyte colony-stimulating factor (g-csf) or g-csf plus chemotherapy. however, about 10-30% of patients are unab...

Transplantation with 2-5 × 10(6) mobilized CD34(+)cells/kg body weight lowers transplantation costs and mortality. Mobilization is most commonly performed with recombinant human G-CSF with or without chemotherapy, but a proportion of patients/donors fail to mobilize sufficient cells. BM disease, prior treatment, and age are factors influencing mobilization, but genetics also contributes. Mobili...

High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34(+) cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor cells. Disruption of the CXCR4/SDF-1 axis b...

The interaction of acute myeloid leukemia (AML) blasts with the bone marrow (BM) microenvironment provides potent protection against both spontaneous apoptosis and chemotherapy. Similar to normal hematopoietic stem cells (HSCs), AML blasts express many of the same adhesion molecules such as CXCR4, VLA-4, VLA-5 and CD44, which allow them to interact with the marrow microenvironment. We and other...

ABSTRACT
 Objective: The aim of this study is to investigate the effect preemptive use plerixafor in patients with lymphoma and multiple
 myeloma which was administered as a single dose who were determined have CD34+ cell count

Autologous stem cell transplantation (ASCT), high-dose chemotherapy followed by hematopoietic stem cell rescue, is a widely used therapeutic strategy especially for some patients with hematological malignancies such as malignant lymphoma or multiple myeloma (MM). Because successful ASCT is crucial in these patients for improving overall survival [1], collection of a sufficient number of hematop...

AMD3100, also known as plerixafor, was originally developed as an anti-human immunodeficiency virus (HIV) drug, and later characterized as a C-X-C chemokine receptor type 4 (CXCR4) antagonist. Previous reviews have focused on the application of AMD3100 in the treatment of HIV, but a comprehensive evaluation of AMD3100 in the treatment of leukemia, solid tumor, and diagnosis is lacking. In this ...